Doximity Stock News

Cicero (OTCMKTS:CICN) and Doximity (NASDAQ:DOCS) are both computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of recent recommendations and price targets for Cicero and Doximity, []

Marshall Wace North America L.P. acquired a new stake in Doximity, Inc. (NASDAQ:DOCS) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 54,472 shares of the companys stock, valued at approximately $3,170,000. Other large investors have also made changes to their []

Related Stocks: ICLR , TMO , GLOB , HTGC , OMCL , TECH , MRVI , DOCS , MRNA , AVTR , STLD , CPRI , BRK.B , SMG , TKR , PNR , TFX , GM ,

In the last trading session, 19.51 million Doximity Inc. (NYSE:DOCS) shares changed hands as the companys beta touched 0. With the companys per share price at $73.48 changed hands at -$3.21 or -4.19% during last session, the market valuation stood at $14.38B. DOCSs last price was a discount, traded about -46.69% off its 52-week high Doximity Inc. (NYSE: DOCS) Stock Could Make A -22.48% Loss Read More »

This recent research compilation on global Patient Scheduling Applications market is a versatile, future ready analytical survey replicating trend assessment, an in-depth assessment of market valuation and revenue generation trends with insights on profit models, competition spectrum and associated vendor strategies illustrated by leading players and contributing market participants investing aggressively in global Patient Scheduling []

Doximity (NASDAQ:DOCS) had its target price increased by Canaccord Genuity from $70.00 to $75.00 in a report released on Wednesday morning, The Fly reports. Canaccord Genuity currently has a buy rating on the stock. Several other brokerages have also recently weighed in on DOCS. Piper Sandler lifted their price target on Doximity from $68.00 to []

Doximity (NASDAQ:DOCS) had its target price upped by Piper Sandler from $68.00 to $81.00 in a research report sent to investors on Wednesday, The Fly reports. The brokerage currently has an overweight rating on the stock. A number of other research analysts have also weighed in on DOCS. Morgan Stanley increased their price target on []

Doximity (NASDAQ:DOCS) had its price target upped by The Goldman Sachs Group from $40.00 to $45.00 in a report published on Wednesday, Briefing.com reports. The brokerage currently has a neutral rating on the stock. A number of other research firms have also recently weighed in on DOCS. Piper Sandler boosted their price objective on shares []

Jeff Tangney, Doximity CEO, joins 'TechCheck' to discuss the company's Q2 earnings results where Doximity saw an 8% beat on the top line.

Doximity, Inc. (DOCS) CEO Jeffrey Tangney on Q2 2022 Results - Earnings Call Transcript

Amazing market penetration and untapped revenue potential make a nice combination.

Five large-cap (market capital > $10 billion) stocks will report earnings results next week. These are: DHI, RNG, DOCS, DIS and AFRM.

Stock market hits resistance as yields keep rising; Microsoft, Nvidia at key levels; Doximity tumbles. Investor's Business Daily has been helping people invest smarter results by providing exclusive s

Doximity has seen tremendous share price growth since its IPO, and if it succeeds in expanding its market opportunity, this could continue.

The healthcare industry is changing. Investors should adapt.